Spain · Delayed Price · Currency is EUR Ligand Pharmaceuticals Statistics
Total Valuation
BME:NHH has a market cap or net worth of EUR 2.83 billion. The enterprise value is 4.93 billion.
| Market Cap | 2.83B |
| Enterprise Value | 4.93B |
Important Dates
The last earnings date was Wednesday, July 23, 2025.
| Earnings Date | Jul 23, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BME:NHH has 435.65 million shares outstanding. The number of shares has decreased by -0.00% in one year.
| Current Share Class | 435.65M |
| Shares Outstanding | 435.65M |
| Shares Change (YoY) | -0.00% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.00% |
| Float | 17.90M |
Valuation Ratios
The trailing PE ratio is 11.19 and the forward PE ratio is 14.58.
| PE Ratio | 11.19 |
| Forward PE | 14.58 |
| PS Ratio | 1.14 |
| PB Ratio | 2.22 |
| P/TBV Ratio | 3.00 |
| P/FCF Ratio | 5.49 |
| P/OCF Ratio | 4.17 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.85, with an EV/FCF ratio of 9.57.
| EV / Earnings | 19.50 |
| EV / Sales | 1.99 |
| EV / EBITDA | 6.85 |
| EV / EBIT | 11.67 |
| EV / FCF | 9.57 |
Financial Position
The company has a current ratio of 0.74, with a Debt / Equity ratio of 1.88.
| Current Ratio | 0.74 |
| Quick Ratio | 0.70 |
| Debt / Equity | 1.88 |
| Debt / EBITDA | 3.33 |
| Debt / FCF | 4.65 |
| Interest Coverage | 3.52 |
Financial Efficiency
Return on equity (ROE) is 22.11% and return on invested capital (ROIC) is 7.37%.
| Return on Equity (ROE) | 22.11% |
| Return on Assets (ROA) | 5.96% |
| Return on Invested Capital (ROIC) | 7.37% |
| Return on Capital Employed (ROCE) | 11.40% |
| Revenue Per Employee | 169,227 |
| Profits Per Employee | 17,270 |
| Employee Count | 15,327 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 48.04 |
Taxes
In the past 12 months, BME:NHH has paid 49.78 million in taxes.
| Income Tax | 49.78M |
| Effective Tax Rate | 16.10% |
Stock Price Statistics
The stock price has increased by +61.85% in the last 52 weeks. The beta is 1.55, so BME:NHH's price volatility has been higher than the market average.
| Beta (5Y) | 1.55 |
| 52-Week Price Change | +61.85% |
| 50-Day Moving Average | 6.30 |
| 200-Day Moving Average | 5.94 |
| Relative Strength Index (RSI) | 69.99 |
| Average Volume (20 Days) | 15,121 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BME:NHH had revenue of EUR 2.48 billion and earned 252.79 million in profits. Earnings per share was 0.58.
| Revenue | 2.48B |
| Gross Profit | 1.67B |
| Operating Income | 422.22M |
| Pretax Income | 309.17M |
| Net Income | 252.79M |
| EBITDA | 526.86M |
| EBIT | 422.22M |
| Earnings Per Share (EPS) | 0.58 |
Balance Sheet
The company has 350.00 million in cash and 2.40 billion in debt, giving a net cash position of -2.05 billion or -4.70 per share.
| Cash & Cash Equivalents | 350.00M |
| Total Debt | 2.40B |
| Net Cash | -2.05B |
| Net Cash Per Share | -4.70 |
| Equity (Book Value) | 1.28B |
| Book Value Per Share | 2.80 |
| Working Capital | -233.26M |
Cash Flow
In the last 12 months, operating cash flow was 677.82 million and capital expenditures -162.57 million, giving a free cash flow of 515.25 million.
| Operating Cash Flow | 677.82M |
| Capital Expenditures | -162.57M |
| Free Cash Flow | 515.25M |
| FCF Per Share | 1.18 |
Margins
Gross margin is 67.26%, with operating and profit margins of 17.05% and 10.21%.
| Gross Margin | 67.26% |
| Operating Margin | 17.05% |
| Pretax Margin | 12.48% |
| Profit Margin | 10.21% |
| EBITDA Margin | 21.27% |
| EBIT Margin | 17.05% |
| FCF Margin | 20.80% |
Dividends & Yields
BME:NHH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 1.89% |
| Buyback Yield | 0.00% |
| Shareholder Yield | n/a |
| Earnings Yield | 8.94% |
| FCF Yield | 18.22% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BME:NHH has an Altman Z-Score of 1.08 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.08 |
| Piotroski F-Score | 7 |